BioSpace News Archive

Organizations focused on social drivers of health invited to submit funding applications through March 20

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the postponement of its Investor Day scheduled for Thursday, March 12th, 2020 to a future date due to concerns related

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today the rescheduling of its fourth quarter and annual 2019 financial results and company update from Wednesday, March 11, 2020 to Wednesday, March 18, 2020 after market close.

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 70,000 shares of the company’s common stock, at a per share exercise price of $3.89, the closing trading price on March 6, and restricted stock units to acquire 35,000 shares of the company’s common stock.

Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that its Board of Directors has approved the issuance of 555,000 stock options, including 465,000 options granted to officers, directors and investor relations personnel of the Corporation.

Huntington Hospital’s board of directors volunteer their time and talent to benefit the health of our community.

BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a Restricted Share Unit Plan (the “RSU Plan”).